Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep63 | Adrenal cortex (to include Cushing's) | ECE2017

Treatment with modified-release hydrocortisone for 6 months: A clinical audit in 15 patients with adrenal insufficiency

Steffensen Charlotte , Andersen Marianne , Feldt-Rasmussen Ulla , Kistorp Caroline , Jorgensen Jens Otto L

Background: Patients with adrenal insufficiency (AI) exhibit increased morbidity, mortality and impaired quality of life (QoL) and conventional hydrocortisone replacement does not mimic the endogenous circadian pattern and may compromise adherence. A modified – release hydrocortisone formulation (Plenadren) for once-daily use is licensed in order to meet these needs.Objective: To audit the effects of treatment change from HC to Plenadren in an out-p...

ea0041ep595 | Endocrine tumours and neoplasia | ECE2016

Biochemical assessment of disease control in acromegaly: reappraisal of the glucose suppression test in somatostatin analogue (SA) treated patients

Arlien-Soborg Mai C. , Alvarson Elin , Dal Jakob , Jorgensen Jens Otto L.

Context: The nadir serum GH level during glucose suppression (OGTT) is recommended in patients treated by surgery, but not during SA treatment. We have shown that patients considered controlled by SA don’t suppress serum GH during OGTT and have impaired disease-specific QoL as compared to patients controlled by surgery. We hypothesize SA treated patients also don’t suppress GH in response to mixed meals.Aim: To compare GH levels during two mixe...

ea0070aep676 | Pituitary and Neuroendocrinology | ECE2020

European Society of Endocrinology audit and multi-country comparison of Adult Growth Hormone Deficiency (AGHD) treatment in clinical practice in Europe and Australia; –how closely are protocols and best practice recommendations followed

Martel-Duguech Luciana , Screen Nik , Jorgensen Jens Otto L , Korbonits Marta , Johannsson Gudmundur , Webb Susan M

Background: Current guidelines recommend that susceptible patients should be tested and treated for AGHD. Still, it is not universally recognised as a distinct entity and reimbursement of GH replacement therapy is not available in some countries.Aim: 1) to record current practice of AGHD management throughout Europe and benchmark it against existing guidelines, 2) to evaluate educational status of health care professionals.Patients...

ea0049gp17 | Adrenal 2 | ECE2017

Hypercortisolism is prevalent in newly diagnosed type 2 diabetes: a prospective study of 384 consecutive patients

Steffensen Charlotte , Dekkers Olaf M , Lyhne Johanne , Poulsen Per L , Rungby Jorgen , Sorensen Henrik T , Jorgensen Jens Otto L

Background: Cross-sectional studies in small and selected populations indicate a relatively high prevalence of incipient and/or subclinical Cushing’s syndrome (CS) in patients with type 2 diabetes (T2D), which could have therapeutic implications.Aim: To estimate the prevalence of CS in a large, unselected cohort of recently diagnosed T2D patients.Methods: A total of 384 consecutive out – patients with T2D diagnosed after ...

ea0041ep25 | Adrenal cortex (to include Cushing's) | ECE2016

Low positive predictive value of midnight salivary cortisol measurement to detect hypercortisolism in type 2 diabetes

Steffensen Charlotte , Thomsen Henrik Holm , Dekkers Olaf M , Christiansen Jens S , Rungby Jorgen , Jorgensen Jens Otto L

Background: Hypercortisolism is prevalent in type 2 diabetes (T2D), but analytical and functional uncertainties prevail. Measurement of salivary cortisol is considered an expedient screening method for hypercortisolism, but its usefulness in the context of T2D is uncertain.Aim: To compare late night salivary cortisol (LNSC) with the 1 mg overnight dexamethasone suppression test (DST), which was considered ‘reference standard’, in T2D.<p cla...

ea0022p229 | Clinical case reports and clinical practice | ECE2010

Dose of growth hormone (GH) and not IGFI level at treatment start influences treatment outcome in GH deficient adults (GHDA): Data from the NordiNet International Outcome Study (IOS)

Jorgensen Jens Otto L , Weber Matthias M , Hoybye Charlotte , Pedersen Birgitte T , Rakov Viatcheslav , Christiansen Jens Sandahl

Background: Serum IGFI measurements are used during GH replacement in GHDA for titration of the GH dose, to monitor compliance and to avoid overdosing, but it is uncertain if pretreatment IGFI is a determinant of the GH dose or the response to GH treatment.Methods: Data from the NordiNet IOS have been analyzed to determine pretreatment serum IGFI concentrations in GHDA and to analyze if they influence the GH starting dose and/or the therapeutic response ...

ea0022p264 | Developmental endocrinology | ECE2010

Baseline characteristics and serum IGF1 levels in GH deficient (GHD) patients treated in the transition phase from adolescence into adulthood: data from the NordiNet International Outcome Study (IOS)

Weber Matthias M , Blankenstein Oliver , Jorgensen Jens Otto L , Pedersen Birgitte T , Rakov Viatcheslav , Christiansen Jens Sandahl

Background: Data from several clinical studies have demonstrated the benefit of GH treatment in relation to bone mineral density and body composition in young adults who received GH treatment in childhood due to GHD1–3. There are recommendations to use a higher GH dose in the transition phase compared to the GH dose required during adulthood to mimic the endogenous GH secretion4,5.Methods: Data from NordiNet IOS have been analy...

ea0041oc13.2 | Pituitary Clinical | ECE2016

Growth hormone and insulin signalling after acute GH exposure in patients with controlled acromegaly: impact of surgery versus somatostatin analog treatment

Dal Jakob , Lundby Hoyer Katrine , Pedersen Steen B , Magnusson Nils , Bjerrring Peter , Frystyk Jan , Moller Niels , Jessen Niels , Jorgensen Jens Otto L

Background: Somatostatin analogue treatment (SA) is used in acromegaly to suppress GH secretion and tumour growth. In addition, SA also suppresses insulin secretion and may impact on GH signalling in peripheral tissues.Objective: To compare GH and insulin signalling in skeletal muscle and adipose tissue in vivo before and after a single exogenous GH bolus in patients with acromegaly controlled by either surgery alone or by ongoing treatment with a slow-r...